LH-RH Agonists in the Treatment of Ovarian Cancer
Ovarian carcinoma is one of the most common causes of cancer death in women. During the last decade there have been some advances in surgical, radiation, and cytotoxic chemotherapy of this malignancy. The overall results of these treatments, however, are still disappointing (MRC Gynecologic Cancer Working Party 1990; Averette and Donato 1990; Blackledge and Lawton 1989). Aggressive chemotherapy is burdened with severe acute side effects. In addition, chemotherapy in ovarian cancer is associated with a 4–12 times higher risk of developing leukemia (Kaldor et al. 1990). One trend in modern oncology has been to reduce at least therapy-induced morbidity, if the efficacy of therapy cannot be improved by increased aggressiveness. With breast and endometrial cancer this has been successfully achieved by the introduction of endocrine treatments, both ablative or additive, that take advantage of the sex-steroid dependence of some of these tumors, as reflected by the presence of estrogen and/or progestin receptors (Desombre et al. 1987). Also many ovarian cancers contain significant amounts of sex-steroid receptors. Therapeutic approaches, however, using either antiestrogens or progestins, have not been satisfying (for review, see Desombre et al. 1987; Rao and Slotman 1991).
KeywordsOvarian Cancer Ovarian Cancer Cell Line Advanced Ovarian Cancer Luteinizing Hormone Release Hormone Human Granulosa Cell
Unable to display preview. Download preview PDF.
- Kaldor JM, Day NE, Petterson F, Clarke EA, Pedersen D, Mehnert W, Bell J, Host H, Prior P, Karjalainen S, Neal F, Koch M, Band P, Choi W, Kirn VP, Arslan A, Zarén B, Belch AR, Storm H, Kittelmann B, Fraser P, Stovall M (1990) Leukemia following chemotherapy for ovarian cancer. N Engl J Med 322:1–6PubMedCrossRefGoogle Scholar
- Kauppila A, Martikainen H, Pentinen J, Reinilä M (1990) GnRH-agonist analogue treatment of ovarian granulosa cell malignancies. Gynecol Endocrinol 4 [Suppl 2]:97Google Scholar
- Kullander S, Rausing A, Schally AV (1987) LH-RH agonist treatment in ovarian cancer. In: Klijn JGM (ed) Hormonal manipulation of cancer: peptides, growth factors and new (anti) steroidal agents. Raven, New York, pp 353–356Google Scholar
- Lee MT, Liebow C, Kramer AR, Schally AV (1991) Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphoryla-tion and dephosphorylation of tyrosine residues of specific protein substrates in various tumors. Proc Natl Acad Sci USA 88:1656–1660PubMedCrossRefGoogle Scholar
- Levy J, Segal T, Wiznitzer A, Insler V, Sharoni Y (1989) Molecular mechanisms of GnRH action on mammary tumors and uterine leiomyomata. In: Vickery BH, Lunenfeld B (eds) GnRH-Analogues in cancer and human reproduction, vol 1. Kluwer, Dordrecht, pp 127–136Google Scholar
- Mayer A (1925) Klinik der Ovarialtumoren, Ätiologie. In: Halban J, Seitz L (eds) Biologie und Pathologie des Weibes, vol 5, part 2. Urban und Schwarzenberg, München, pp 877–881Google Scholar
- Ohtani K (1990) Effects of gonadotropin on the growth of malignant ovarian neoplasms assessed by subrenal capsule assay. Nippon Sanka Fujinka Gakki Zasshi 42:579–585Google Scholar
- Ohtani K, Sakamoto H, Konbai D (1990) Antagonistic effects of GnRH agonist on gonadotropin stimulated proliferation of human ovarian cancer cell line. Gynecol En-docrinol 4 (Suppl 2):98Google Scholar
- Olshausen R (1877) Die Krankheiten der Ovarien, Ätiologie. In: Billroth T (ed) Handbuch der Frauenkrankheiten, vol 6. Enke, Stuttgart, pp 74–78Google Scholar
- Olsson JH, Akesson I, Hillensjoe T (1990) Effects of a gonadotropin-releasing hormone agonist on progesterone formation in cultured human granulosa cells. Acta Endocrinol (Copenh) 122:427–431Google Scholar